Viking TherapeuticsVKTX
About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Employees: 34
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
93% more call options, than puts
Call options by funds: $486M | Put options by funds: $252M
72% more repeat investments, than reductions
Existing positions increased: 174 | Existing positions reduced: 101
60% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 58
33% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 8 (+2) [Q3]
20% more capital invested
Capital invested by funds: $4.43B [Q2] → $5.3B (+$866M) [Q3]
8% more funds holding
Funds holding: 385 [Q2] → 416 (+31) [Q3]
0.62% more ownership
Funds ownership: 75.77% [Q2] → 76.39% (+0.62%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Joseph Pantginis 29% 1-year accuracy 118 / 401 met price target | 200%upside $102 | Buy Reiterated | 17 Jan 2025 |
Piper Sandler Biren Amin 15% 1-year accuracy 3 / 20 met price target | 117%upside $74 | Overweight Initiated | 2 Dec 2024 |
B. Riley Securities Mayank Mamtani 26% 1-year accuracy 6 / 23 met price target | 220%upside $109 | Buy Initiated | 22 Nov 2024 |
Financial journalist opinion
Based on 37 articles about VKTX published over the past 30 days
